Related Experiment Video
Updated: Jan 11, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Development of a CTL Epitope-Based Vaccine Targeting Tumor Antigens in Esophageal Cancer: An Immunoinformatic Study
1Department of Oncology, Ankang People's Hospital, Ankang 725000, China.
Background:
Esophageal cancer is a highly aggressive malignancy with poor global survival rates and limited efficacy from conventional therapies. Immunotherapy has shown promise, yet its effectiveness remains limited as a standalone approach. The identification of tumor-specific antigens offers a targeted strategy for therapeutic vaccine development.
Objectives:
This study aimed to design a cytotoxic T lymphocyte (CTL)-based multi-epitope vaccine targeting immunodominant tumor-specific antigens associated with esophageal cancer using computational immunoinformatics and structural bioinformatics techniques.
Materials And Methods:
Fourteen validated CTL epitopes were selected based on immunogenicity, antigenicity (VaxiJen), IFN-γ inducibility, and structural stability. These epitopes were linked using AAY linkers to enhance processing by MHC class I molecules. The vaccine construct was evaluated for physicochemical properties, allergenicity, and toxicity. Structural modeling was performed using Robetta, and the model was validated by ProSA, ERRAT, and Ramachandran plot analysis. Molecular docking with TLR4 and MHC-I alleles, molecular dynamics simulation (iMODS), and MM/GBSA free energy calculations were used to assess binding affinity and structural stability. Immune simulations and population coverage analyses were also performed.
Results:
The designed vaccine showed strong antigenicity (0.6199), was non-toxic and non-allergenic, and exhibited excellent stability and solubility. Molecular docking revealed strong binding with TLR4 (-1125.3 kcal. moL-1), and MM/GBSA analysis confirmed favorable binding free energy (-93.41 kcal. moL-1). Immune simulations indicated robust T-cell responses. Population coverage was highest in Oceania (64.14%) and East Asia (60.66%). Codon optimization and in silico cloning confirmed high expression potential in E. coli.
Conclusion:
The vaccine demonstrates strong potential as a safe, stable, and broadly applicable immunotherapeutic candidate against esophageal cancer, pending experimental validation.
Insights
This study designed a novel multi-epitope vaccine targeting esophageal cancer using computational methods. The vaccine is safe, stable, and shows potential for robust T-cell responses, offering a promising new immunotherapy candidate.
Area of Science:
- Computational immunoinformatics and structural bioinformatics applied to vaccine design.
- Oncology and immunology research focused on novel cancer therapies.
Background:
- Esophageal cancer is aggressive with poor outcomes and limited treatment options.
- Current immunotherapies show promise but are not fully effective alone.
- Targeting tumor-specific antigens is a key strategy for developing effective vaccines.
Purpose of the Study:
- To design a cytotoxic T lymphocyte (CTL)-based multi-epitope vaccine against esophageal cancer.
- The vaccine targets immunodominant tumor-specific antigens identified through computational analysis.
Main Methods:
- Selection of 14 validated CTL epitopes based on immunogenicity, antigenicity, and stability.
- Epitopes were linked and the vaccine construct was evaluated for physicochemical properties, toxicity, and allergenicity.
- In silico analyses included structural modeling, molecular docking, molecular dynamics simulations, and immune simulations.
Main Results:
- The designed vaccine construct demonstrated strong antigenicity, non-toxicity, and non-allergenicity.
- Favorable binding affinity to TLR4 and MHC-I alleles was confirmed, along with structural stability and solubility.
- Immune simulations predicted robust T-cell responses, with high population coverage in East Asia and Oceania.
Conclusions:
- The in silico designed vaccine is a promising, safe, and stable immunotherapeutic candidate for esophageal cancer.
- Further experimental validation is required to confirm its efficacy in treating esophageal cancer.
- This computational approach offers a viable strategy for developing targeted cancer vaccines.
